Emmanuelle J Meuillet, PhD, VP Research and Development
Emmanuelle J. Meuillet is an accomplished scientist, inventor, and entrepreneur focusing on drug discovery and development. Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France). She completed post-doctoral training at the Children’s Memorial Hospital at Northwestern University in Chicago and at the University of Arizona Comprehensive Cancer Center in Tucson. Over the years, Dr. Meuillet has managed many NIH funded programs bringing in over $9M for research in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects. She founded two biotech companies, Phusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules. Dr. Meuillet is a consultant for the NIH, DoD, and various foundations and organizations in the US and Europe. She is the author of more than fifty peer-reviewed manuscripts and reviews, she is an inventor on three patents and she belongs to several editorial boards for specialized cancer journals.
Audrey Jakubowski, Ph.D. VP of Regulatory Affairs and QA
Dr. Jakubowski came to Targazyme after a long career in both big and small pharma. She started her career at Bristol Myers, working with dermatological products and then moving to the Bristol Myers Research Center in Wallingford, CT, where she built and led a regulatory group that focused on building a single, international dossier that could be submitted around the globe. During that time, Dr. Jakubowski prepared registration plans and documents for drugs in cancer, cardiovascular, central nervous system, anti-infective and anti-HIV areas for European, Canadian and Japanese submissions. Dr. Jakubowski went on to DuPont, where she was the head of Global Regulatory Affairs for the pharmaceutical division at DuPont where she had responsibility for investigational drugs as well as marketed products, generic drugs, and radiopharmaceuticals. During her 15th year in big pharma, Dr. Jakubowski was responsible for submitting multiple New Drug Applications, both in the U. S. and abroad. She also was the regulatory lead for two FDA advisory committee meetings in the U.S. Dr. Jakubowski was an elected member of the Pharmaceutical Research and Manufacturer’s Association (PhRMA) Regulatory Affairs Committee and was an invited speaker at many professional meetings. Dr. Jakubowski came to California to join Systemix, a cell therapy company, as their Vice President of Regulatory Affairs and Quality Assurance. Dr. Jakubowski went on to SuperGen where she also had responsibility for regulatory affairs and quality assurance and submitted two NDAs for cancer drugs. Dr. Jakubowski went on to support the company’s focus on new molecules that were early on in development, which she continued to do until she retired in 2009. Dr. Jakubowski left retirement to join Targazyme because she feels that the platform technology that Targazyme has developed has the potential to help so many people who are desperate for help with their serious diseases. Dr. Jakubowski received her Ph.D in Physical Chemistry from S.U.N.Y. Buffalo. She also completed a PostDoctoral Fellowship at S.U.N.Y. Buffalo Department of Medicine and another at Rosewell Park Memorial Institute in Buffalo, N.Y.
Richard Martin, Ph.D. VP of CMC and Head of Operations
Dr. Martin is an accomplished pharmaceutical executive with over 20 years of research and development experience in the fields of antibacterial, inflammation, oncology, antiviral, antifungal, cardiovascular and metabolic diseases, sexual dysfunction, as well as glycosciences. An excellent track record of bringing hits to leads, optimizing compounds into development candidates, as well as managing the chemistry, manufacturing, and regulatory activities for both clinical stage and approved drugs. He directed many successful programs of which 4 compounds have entered clinical trials. Collaborated closely with several Big Pharma companies to advance these development compounds following licensing of the assets and participated in joint steering teams. He was instrumental in the CMC efforts that led to the approval of Apricus Biosciences’ first drug Vitaros® in Canada and Europe. Dr. Martin initially served at Tanabe Research Laboratories before joining X-Ceptor therapeutics, which was acquired by Exelixis for their valuable metabolic disease programs. He then held the position of Director of Chemistry at Exelixis before joining RetroVirox as Senior Director of Chemistry, founding partner and investor. Dr. Martin then served as Vice President of Chemistry and Manufacturing at Apricus Biosciences (NexMed USA) where he led the chemistry, manufacturing and supply chain activities at the company. Dr. Martin obtained his Ph.D. from the University of Toronto and pursued postdoctoral studies at The Scripps Research Institute in San Diego with professor Chi-Huey Wong, a pioneer in the field of glycosciences. Dr. Martin has over 30 patent applications, 26 of which have already been granted in the US, over 25 publications in peer-reviewed journals and presentations at various scientific meetings.